- An analysis of 3 prospective trials shows no increased incidence of colorectal cancer (CRC) associated with use of proton pump inhibitors (PPIs) or H2 receptor agonists (H2RAs).
Why this matters
- PPI and H2RA use is becoming more common and has led to concerns about long-term risk for CRC.
- Pooled analysis from 3 prospective studies (175,871 PPI users; 208,831 H2RA users).
- Funding: NIH; others.
- CRC was not associated (HRs; 95% CIs) with PPI use at:
- Baseline: 0.89 (0.71-1.12).
- After 8-10-year lag: 1.12 (0.78-1.59).
- CRC was not associated with H2RA use after an 8-10-year lag:
- HR, 1.02 (95% CI, 0.81-1.28).
- Baseline H2RA use was associated with a lower risk for CRC:
- HR, 0.76 (95% CI, 0.60-0.95).
- There was no association between CRC and duration of PPI (Ptrend=.21) or H2RA (Ptrend=.95) use.
- Medication use was self-reported.